Phase II trial of piperazinedione in malignant melanoma: a report by the Southeastern Cancer Study Group.

Abstract

Forty-one evaluable patients with malignant melanoma resistant to other chemotherapeutic agents received 9 mg/m2 of piperazinedione every 3 weeks. Two patients had partial responses and one additional patient had stable disease. One of the partial responses occurred in a patient with subcutaneous metastases and the other occurred in a patient with pulmonary and osseous metastases. Both antitumor responses occurred in the 17 patients with a performance status of greater than or equal to 80%. The dose-limiting toxicity was myelosuppression; thrombocytopenia was more frequently observed than granulocytopenia.

• Authors: C A Presant, A A Bartolucci, P Ungaro, R Oldham
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 63 Issue 8 Pg. 1367-9 (Aug 1979) ISSN: 0361-5960 [Print] United States
• PMID: 476710 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antibiotics, Antineoplastic
• Piperazines
• 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione

Topics

• Antibiotics, Antineoplastic (therapeutic use)
• Bone Neoplasms (drug therapy, secondary)
• Drug Evaluation
• Humans
• Lung Neoplasms (drug therapy, secondary)
• Melanoma (drug therapy, secondary)
• Piperazines (therapeutic use)
• Skin Neoplasms (drug therapy)
• Thrombocytopenia (chemically induced)